TEM:NSD-Tempus AI, Inc. Class A Common Stock (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 34.79

Change

-0.12 (-0.34)%

Market Cap

USD 7.92B

Volume

1.17M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company also offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a collaboration with united therapeutics to study use of AI to detect patients at risk for pulmonary hypertension. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc in January 2023. Tempus AI, Inc was incorporated in 2015 and is headquartered in Chicago, Illinois.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
GEHC GE HealthCare Technologies Inc..

+0.08 (+0.10%)

USD 37.81B
HQY HealthEquity Inc

+0.59 (+0.62%)

USD 8.82B
WAY Waystar Holding Corp. Common S..

+0.83 (+2.25%)

USD 4.47B
BTSG BrightSpring Health Services, ..

+0.04 (+0.23%)

USD 3.18B
PRVA Privia Health Group Inc

-0.01 (-0.05%)

USD 2.52B
OMCL Omnicell Inc

-1.30 (-2.92%)

USD 2.13B
PINC Premier Inc

+0.13 (+0.61%)

USD 2.08B
WGS GeneDx Holdings Corp.

+1.00 (+1.31%)

USD 2.03B
GDRX Goodrx Holdings Inc

-0.03 (-0.66%)

USD 1.87B
CERT Certara Inc

-0.04 (-0.37%)

USD 1.75B

ETFs Containing TEM

REMX VanEck Rare Earth/Strateg.. 6.07 % 0.59 %

+0.57 (+0%)

N/A
SPXZ 1.50 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 7.92B 95% A 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector